45
Participants
Start Date
September 20, 2022
Primary Completion Date
January 15, 2025
Study Completion Date
September 30, 2028
Abemaciclib
Orally
Irinotecan
IV
Temozolomide
Orally
The Children's Hospital at Westmead, Westmead
Peter MacCallum Cancer Centre, Melbourne
Royal Children's Hospital, Melbourne
Charité Campus Virchow-Klinikum, Berlin
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Infantil Universitario Niño Jesús, Madrid
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario La Paz, Madrid
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux
IRCCS Istituto Ortopedico Rizzoli, Bologna
Hospital Universitario Virgen Del Rocio, Seville
Universitätsklinikum Essen, Essen
Hospital Universitari i Politecnic La Fe, Valencia
Riley Hospital for Children at Indiana University Health, Indianapolis
Washington University, St Louis
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Phoenix Children's Hospital, Phoenix
The Regents of the University of California - Los Angeles (UCLA Pediatrics), Los Angeles
Lifespan Cancer Institute, Providence
Centre Leon Berard, Lyon
Fondazione Policlinico Universitario Agostino Gemelli, Rome
Hyogo Prefectural Kobe Children's Hospital, Kobe
National Cancer Center Hospital, Chuo-ku
Kyushu University Hospital, Fukuoka
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Sant Joan de Déu, Esplugues de Llobregat
Hospital de la Santa Creu i Sant Pau, Barcelona
Eli Lilly and Company
INDUSTRY